Skip to content
Company Analysis

NeoGenomics, Inc. NEO

A comprehensive view of key metrics, scores, and financial health for NeoGenomics, Inc.

Overview of NeoGenomics, Inc.

NEO NCM
Healthcare Diagnostics & Research Small Cap
NeoGenomics, Inc. (NEO), is a Small Cap company, in the Diagnostics & Research industry, last closed at $7.88, about 23.5% undervalued vs fair value, -19.9% 1Y return, placing in the top 10% of its sector.
$7.88
-1.25%
As of March 13, 2026
Previous close • Vol 90d: 45.2%
52-Week Range
Market Cap
$1.16B
Enterprise Value
$1.48B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for NeoGenomics, Inc..

Top Beats

Quick Facts

Website https://www.neogenomics.com
HQ Fort Myers, FL
Employees 2,500
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$8
$10
$11
Current: $7.88 +24% vs base

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$727.3M
10.1%%
Gross Profit
$282.5M
-2.6%%
Operating Income
$-66.1M
22.7%%
Net Income
$-108.0M
-37.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
31.5%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
7
Active Leaks
1/7
Improving
0
High Impact
7
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating NeoGenomics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
56
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
50
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 85% Coverage
Trade-Off Triangle Visualization A ternary plot showing NEO's balance between Growth (33.8%), Profitability (34.1%), and Safety (32.1%). Growth 34% Safety 32% Profitability 34%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

51th percentile vs peers
52
Key Signals
Rev Growth YoY 10.1% 55p Revenue CAGR 3Y 12.6% 58p EPS Growth YoY 11.3% 37p
Strengths
  • Current Ratio in top 20% of peers (4.26, 84th percentile)
  • Quick Ratio in top 20% of peers (3.94, 83th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

51th percentile vs peers
52
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
49
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for NeoGenomics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$9.73
- - -
+23.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info